Physician profile
Shudan Wang
NPI 1831432780
$2,873.65
in general payments reported to CMS, 2019-2025
16 companies · $599 in 2025
The $599 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2021: $21.67 · 2022: $388 · 2023: $933 · 2024: $764 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,004 · Education: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.42 |
| Education | $292.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $805.74 | 2022-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $597.72 | 2019-2025 | Tremfya |
| Amgen INC. | $344.69 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Astrazeneca Pharmaceuticals LP | $211.13 | 2022-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $170.81 | 2023-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $161.10 | 2022-2024 | Benlysta, Nucala |
| Csl Behring | $135.67 | 2023-2025 | Hizentra, Haegarda |
| Ucb, INC. | $110.61 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $75.29 | 2022 | |
| Alexion Pharmaceuticals, INC. | $66.15 | 2025 | Ultomiris |
| Horizon Therapeutics Plc | $51.10 | 2022-2023 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $40.57 | 2025 | Cuvitru |
| Kaleo, INC. | $36.38 | 2022-2023 | Auvi-Q |
| Ionis Pharmaceuticals, INC. | $29.12 | 2025 | Dawnzera |
| Genzyme Corporation | $21.67 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $15.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shudan Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.